Cardiol to abandon COVID study of cannabis drug to focus on heart diseases trials
Solskin
Cardiol Therapeutics (NASDAQ:CRDL) said it will discontinue its LANCER trial of CardiolRx for COVID-19 and will prioritize its phase 2 programs of CardiolRx for two heart diseases.
CardiolR…